VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
NUTX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
NUTXNutex Health, Inc.
$167.60$998M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksNUTXBalance Sheet

Nutex Health, Inc. (NUTX) Balance Sheet

13Y historyFree accessUpdated daily

The company has achieved a notable improvement in financial stability, successfully reducing its debt-to-equity ratio from 3.80 in 2024Q3 to 0.60 by 2026Q1.

NUTX Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'11Dec'10
Total Current Assets579.65M538.81M292.48M90.85M97.97M154.02M135.51M45.74M305.42K55.08K507.93K7.63M1.76M2.22M
Cash & Short-Term Investments207.35M185.57M43.58M22M34.26M36.12M25.51M8M119.27K9.45K10.52K122.29K224.8K465.55K
Cash Only207.35M185.57M43.58M22M34.26M36.12M25.51M8M119.27K9.45K10.52K122.29K224.8K465.55K
Short-Term Investments00000000000000
Accounts Receivable339.56M325.42M236.05M62.78M58.32M114.76M108.14M36.14M186.15K6.25K15K0720.87K613.65K
Days Sales Outstanding145.94135.71179.5292.5297.06126.34144.04135.91743.642.55--103.24176.87
Inventory4.68M2.87M2.85M3.39M3.53M2.81M1.73M899.91K27.07K00000
Days Inventory Outstanding2.562.433.675.816.336.755.41-158.62-----
Other Current Assets28.06M24.95M10M01.87M323.28K00-27.07K39.38K482.41K7.27M754.77K812.73K
Total Non-Current Assets377.67M379.71M362.84M307.4M333.78M240.63M173.05M133.48M144.01K3.27M2.9K3.38K313.77K116.11K
Property, Plant & Equipment342.18M343.9M324.69M269.39M295.15M238.36M170.81M131.28M7.61K3.85K1.18K1.66K18.56K5.09K
Fixed Asset Turnover2.61x2.55x1.48x0.92x0.74x1.39x1.60x0.74x12.00x13.95x--137.30x248.94x
Goodwill13.92M13.92M13.92M17.07M17.01M1.14M1.14M3.47M0000111.03K111.03K
Intangible Assets20.91M21.23M15.53M20.51M21.19M682.65K01.54M2.57M3.27M0000
Long-Term Investments0000000100K116.96K00000
Other Non-Current Assets668K662K711.35K431.13K423.43K456.08K1.1M-2.81M19.43K1.95K1.72K1.72K00
Total Assets957.32M918.52M655.32M398.25M431.75M394.65M308.55M179.22M449.43K3.33M510.83K7.64M2.07M2.33M
Asset Turnover0.96x0.95x0.73x0.62x0.51x0.84x0.89x0.54x0.20x0.02x--1.23x0.54x
Asset Growth %284.88%40.16%64.55%-7.76%9.4%27.9%72.16%39778.36%-86.5%551.63%-93.31%268.48%-11.2%-
Total Current Liabilities184.44M157.91M140.87M58.31M54.86M37.69M31.45M72.13M1.04M959.78K6.38M6.08M288.58K351.62K
Accounts Payable46.45M48.97M13.96M25.28M23.93M17.65M8.63M1.75M567.01K348.35K356K168.97K263.19K326.23K
Days Payables Outstanding34.5541.4717.9643.3542.8442.3227.06-3.32K225.3274.72K93.16K62.81152.04
Short-Term Debt26.27M14.08M17.95M14.18M15.17M10.23M18.65M13.35M477.06K386.19K50K000
Deferred Revenue (Current)00000173.92K38.65K165.56K9.19K9.1K0811.23K00
Other Current Liabilities111.72M8.26M005.61M3.6M-38.65K3.37M332.19K216.14K5.97M5.1M25.39K25.39K
Current Ratio3.14x3.41x2.08x1.56x1.79x4.09x4.31x0.63x0.29x0.06x0.08x1.26x6.10x6.31x
Quick Ratio3.12x3.39x2.06x1.50x1.72x4.01x4.25x0.62x0.27x0.06x0.08x1.26x6.10x6.31x
Cash Conversion Cycle113.9596.66165.2254.9960.5590.77122.39--2.42K-----
Total Non-Current Liabilities330.83M337.18M312.56M260.83M256.56M165.38M129.73M56.26M902.72K000181.69K0
Long-Term Debt298.41M29.17M22.47M26.31M23.05M78.82M81.9M40.88M902.72K00000
Capital Lease Obligations888.23M298.91M290.1M229.37M223.06M86.56M47.83M15.38M000000
Deferred Tax Liabilities32.2M9.09M05.15M10.45M1.75M00000000
Other Non-Current Liabilities24.26M0000-1.75M000000181.69K0
Total Liabilities515.26M495.09M453.43M319.14M311.42M203.07M161.19M128.39M1.95M959.78K6.38M6.08M470.27K351.62K
Total Debt324.68M351.39M340.3M275.76M267.2M178.55M150.12M119.94M1.38M386.19K50K000
Net Debt117.33M165.82M296.72M253.75M232.95M142.43M124.61M111.94M1.26M376.74K39.48K-122.29K-224.8K-465.55K
Debt / Equity0.60x0.83x1.69x3.49x2.22x0.93x1.02x2.36x-0.16x----
Debt / EBITDA1.09x1.19x2.27x--1.00x0.94x3.23x------
Net Debt / EBITDA0.39x0.56x1.98x--0.80x0.78x3.01x------
Interest Coverage9.13x12.01x6.51x-1.97x-32.60x28.35x23.66x10.09x-1.31x-15.35x-173.90x-169.42x--
Total Equity537.81M423.44M201.89M79.11M120.33M191.58M147.37M50.84M-1.5M2.37M-5.87M1.56M1.6M1.99M
Equity Growth %965.17%109.73%155.22%-34.26%-37.19%30%189.89%3495.03%-163.21%140.36%-475.93%-2.58%-19.27%-
Book Value per Share74.9362.6739.5917.9428.4348.4834.3412.28-0.210.57-2.840.761.341.66
Total Shareholders' Equity442.05M329.45M146.34M61.45M95.86M114.65M85.81M28.31M-1.5M2.37M-5.87M1.56M1.6M1.99M
Common Stock7K7K5.51K676.68K650.22K592.79K5.28K4.65K1.77K126.2K39.71K39.68K00
Retained Earnings-239.38M-286.19M-356.89M-409.07M-363.29M102.32M-18.22M-12.57M-5.45M-9.65M-10.23M-2.8M-824.45K-441.06K
Treasury Stock000000000-1M0000
Accumulated OCI00000000000000
Minority Interest95.76M93.99M55.55M17.65M24.46M76.93M61.56M22.53M000000

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Regulatory reimbursement volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Rapid Deleveraging Enhances Financial Flexibility

As reported in financial statements, Nutex Health has successfully reduced its debt-to-equity ratio from 3.80 in 2024Q3 to 0.60 by 2026Q1, signaling a significant shift toward a more conservative capital structure that may provide a buffer against the inherent volatility of its micro-hospital business model.

The dramatic improvement in the debt-to-equity ratio appears driven by both a reduction in total debt and a substantial expansion of the equity base. This trajectory suggests management is prioritizing balance sheet stability, which may be a strategic necessity given the regulatory and reimbursement risks inherent in the emergency care sector.

Liquidity Buffer Strengthens Amid Operations

Based on the company's reported figures, the current ratio has improved from 1.56 in 2023Q4 to 3.14 in 2026Q1, reflecting a robust accumulation of cash reserves that now stand at $207.3 million, providing the firm with significant dry powder for potential future facility expansions or operational contingencies.

The expansion of the current ratio suggests that the company is effectively managing its short-term obligations relative to its liquid assets. Investors should monitor whether this liquidity is being held to offset potential future cash flow volatility or if it represents capital awaiting deployment into new high-acuity nodes.

Equity Base Expansion Masks Losses

According to recent SEC filings, the company's equity base has grown from $61.5 million in 2023Q4 to $442.1 million in 2026Q1, despite the persistence of significant negative retained earnings, which suggests that capital infusions or equity-based financing have been the primary drivers of balance sheet growth.

The disconnect between the rising equity position and the ongoing accumulation of negative retained earnings warrants further investigation into the quality of the capital structure. It appears that the firm is relying on external equity support to sustain its growth, which may dilute long-term shareholder value if operational profitability does not materialize.

Asset Composition Reflects Capital Intensity

As indicated by the balance sheet data, net property, plant, and equipment (PPE) has increased to $342.2 million as of 2026Q1, confirming that the company's business model remains inherently asset-heavy due to the physical requirements of maintaining a decentralized network of 21 emergency-grade micro-hospital facilities.

The concentration of assets in PPE highlights the high fixed-cost nature of the hospital division, which requires consistent patient volume to achieve operating leverage. The relatively low level of goodwill suggests that the asset base is primarily composed of tangible infrastructure, which may offer more tangible value than intangible-heavy peers.

NUTX — Frequently Asked Questions

Quick answers to the most common questions about buying NUTX stock.

What are the total assets of Nutex Health, Inc. (NUTX)?

As of 2025, Nutex Health, Inc. (NUTX) had total assets of $918.5M including $538.8M in current assets.

How much debt does Nutex Health, Inc. (NUTX) have?

Nutex Health, Inc. (NUTX) carries total debt of $351.4M, offset by $185.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Nutex Health, Inc.?

Nutex Health, Inc. (NUTX) has total shareholders' equity (book value) of $329.4M ($62.67 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Nutex Health, Inc.'s current ratio and liquidity?

Nutex Health, Inc. (NUTX) reported a current ratio of 3.41x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.